AR094026A1 - Metodo para activar la celula t helper - Google Patents
Metodo para activar la celula t helperInfo
- Publication number
- AR094026A1 AR094026A1 ARP130104756A ARP130104756A AR094026A1 AR 094026 A1 AR094026 A1 AR 094026A1 AR P130104756 A ARP130104756 A AR P130104756A AR P130104756 A ARP130104756 A AR P130104756A AR 094026 A1 AR094026 A1 AR 094026A1
- Authority
- AR
- Argentina
- Prior art keywords
- molecule
- hla
- drb1
- cells
- dqb1
- Prior art date
Links
- 210000002443 helper t lymphocyte Anatomy 0.000 title abstract 4
- 230000003213 activating effect Effects 0.000 title abstract 3
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 abstract 11
- 108010039343 HLA-DRB1 Chains Proteins 0.000 abstract 11
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 108010065026 HLA-DQB1 antigen Proteins 0.000 abstract 5
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 4
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 4
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Método para activar células T helper, que incluye la etapa de activación de células T helper por adición de un péptido WT1 a células que presentan antígeno, en donde el péptido WT1 tiene la capacidad de unirse con una molécula MHC de clase II seleccionada de molécula HLA-DRB1*08:02, una molécula HLA-DRB1*13:02, una molécula HLA-DRB1*14:03, una molécula HLA-DRB1*14:05, una molécula HLA-DQB1*03:02 y una molécula HLA-DQB1*04:01. Reivindicación 3: Una composición para tratar o prevenir un cáncer que comprende un péptido WT1, un polinucleótido que codifica el péptido WT1, un vector de expresión que contiene el polinucleótido o células que contienen el vector de expresión, en donde la composición se administra a un sujeto que tiene una molécula MHC de clase II seleccionada de una molécula HLA-DRB1*08:02, una molécula HLA-DRB1*13:02, una molécula HLA-DRB1*14:03, una molécula HLA-DRB1*14:05, una molécula HLA-DQB1*03:02 y una molécula HLA-DQB1*04:01. Reivindicación 7: Células que presentan antígeno que presentan un complejo de un péptido antigénico que contiene un péptido WT1 con una molécula MHC de clase II, en donde la molécula MHC de clase II es una molécula MHC de clase II seleccionada de una molécula HLA-DRB1*08:02, una molécula HLA-DRB1*13:02, una molécula HLA-DRB1*14:03, una molécula HLA-DRB1*14:05, una molécula HLA-DQB1*03:02 y una molécula HLA-DQB1*04:01. Reivindicación 14: Una composición farmacéutica para tratar o prevenir un cáncer que comprende, como un ingrediente activo, cualquiera de las células que presentan antígeno de acuerdo con cualquiera de las reivindicaciones 7 - 9, las células T helper de acuerdo con cualquiera de las reivindicaciones 10 - 12 o las células T citotóxicas de acuerdo con la reivindicación 13.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012274494 | 2012-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094026A1 true AR094026A1 (es) | 2015-07-08 |
Family
ID=50978342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130104756A AR094026A1 (es) | 2012-12-17 | 2013-12-16 | Metodo para activar la celula t helper |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9833493B2 (es) |
| EP (1) | EP2933261B1 (es) |
| JP (1) | JP6530192B2 (es) |
| KR (1) | KR102158225B1 (es) |
| CN (2) | CN104995203B (es) |
| AR (1) | AR094026A1 (es) |
| AU (1) | AU2013365067B2 (es) |
| BR (1) | BR112015013697A2 (es) |
| CA (1) | CA2892660C (es) |
| EA (1) | EA201591168A1 (es) |
| ES (1) | ES2805337T3 (es) |
| HK (1) | HK1216755A1 (es) |
| IL (1) | IL239056A0 (es) |
| MX (1) | MX2015007745A (es) |
| MY (1) | MY175935A (es) |
| NZ (1) | NZ708990A (es) |
| PH (1) | PH12015501361A1 (es) |
| SG (2) | SG11201504530VA (es) |
| TW (1) | TWI646970B (es) |
| UA (1) | UA118962C2 (es) |
| WO (1) | WO2014098012A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1696027A4 (en) | 2003-11-05 | 2008-05-14 | Int Inst Cancer Immunology Inc | ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1 |
| WO2007047764A2 (en) | 2005-10-17 | 2007-04-26 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| US9265816B2 (en) | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
| RU2009135802A (ru) | 2007-02-27 | 2011-04-10 | Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. (Jp) | Способ активации хелперных т-клеток и композиция для применения в данном способе |
| US10654892B2 (en) | 2010-10-05 | 2020-05-19 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
| JP6282598B2 (ja) | 2012-01-13 | 2018-02-21 | メモリアル スローン ケタリング キャンサー センター | 免疫原性ｗｔ１ペプチド及びその使用方法 |
| TWI646970B (zh) | 2012-12-17 | 2019-01-11 | 大塚製藥股份有限公司 | 活化輔助ｔ細胞的方法 |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| CA2898099A1 (en) | 2013-01-15 | 2014-07-24 | David A. Scheinberg | Immunogenic wt-1 peptides and methods of use thereof |
| KR20230141904A (ko) * | 2014-12-11 | 2023-10-10 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 혈관 신생병의 면역 요법 |
| CN111647066B (zh) * | 2020-07-01 | 2020-12-18 | 维肽瀛(上海)生物技术有限公司 | Wt1多肽肿瘤抑制剂 |
| CA3228494A1 (en) | 2021-08-12 | 2023-02-16 | International Institute Of Cancer Immunology, Inc. | Pharmaceutical composition and method for treating or preventing cancer |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
| CN1178956C (zh) | 1998-07-31 | 2004-12-08 | 杉山治夫 | 基于癌抑制基因wt1的产物的癌抗原 |
| US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| DE69938970D1 (de) | 1998-09-30 | 2008-08-07 | Corixa Corp | Zusammensetzungen und verfahren für wt1-spezifische immunotherapie |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| AU2001247220A1 (en) | 2000-02-22 | 2001-09-03 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| KR100863853B1 (ko) | 2001-03-22 | 2008-10-15 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 더블유티1 개변 펩티드 |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| WO2003002142A1 (en) | 2001-06-29 | 2003-01-09 | Chugai Seiyaku Kabushiki Kaisha | Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
| EP1447091A4 (en) | 2001-09-28 | 2008-02-13 | Institute Of Can International | NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS |
| JPWO2003028758A1 (ja) | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的ｔ細胞の誘導方法 |
| AU2003242305A1 (en) | 2002-06-12 | 2003-12-31 | Chugai Seiyaku Kabushiki Kaisha | Hla-a24-restricted cancer antigen peptide |
| AU2003262094A1 (en) | 2002-09-12 | 2004-04-30 | Haruo Sugiyama | Cancer antigen peptide preparation |
| DE60329201D1 (de) | 2002-09-20 | 2009-10-22 | Chugai Pharmaceutical Co Ltd | Substituierte wt1-peptide |
| ES2332590T3 (es) | 2003-01-15 | 2010-02-09 | International Institute Of Cancer Immunology, Inc. | Dimero peptidico. |
| JP4566912B2 (ja) | 2003-06-27 | 2010-10-20 | 株式会社癌免疫研究所 | Ｗｔ１ワクチン適応患者の選択方法 |
| EP1696027A4 (en) | 2003-11-05 | 2008-05-14 | Int Inst Cancer Immunology Inc | ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1 |
| DK2186896T3 (en) | 2004-03-31 | 2015-12-21 | Int Inst Cancer Immunology Inc | Cancer antigen peptides derived from WT1 |
| JP4719876B2 (ja) | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド |
| WO2007047764A2 (en) | 2005-10-17 | 2007-04-26 | Sloan Kettering Institute For Cancer Research | Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| ES2352855T3 (es) | 2005-11-30 | 2011-02-23 | International Institute Of Cancer Immunology, Inc. | Nuevos compuestos peptídicos del tumor de wilms. |
| US7420880B2 (en) | 2005-12-29 | 2008-09-02 | Timex Group B.V. | Multimode electronic device with calibrating/setting mechanism |
| ES2587980T3 (es) | 2006-02-22 | 2016-10-28 | International Institute Of Cancer Immunology, Inc | Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene |
| US9265816B2 (en) * | 2006-04-10 | 2016-02-23 | Sloan Kettering Institute For Cancer Research | Immunogenic WT-1 peptides and methods of use thereof |
| EP2479275B1 (en) | 2006-12-28 | 2015-10-28 | International Institute of Cancer Immunology, Inc. | HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same |
| RU2009135802A (ru) * | 2007-02-27 | 2011-04-10 | Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. (Jp) | Способ активации хелперных т-клеток и композиция для применения в данном способе |
| MX343633B (es) | 2007-03-05 | 2016-11-11 | Int Inst Cancer Immunology Inc | Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos. |
| AR076349A1 (es) * | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| US10654892B2 (en) * | 2010-10-05 | 2020-05-19 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
| TWI646970B (zh) | 2012-12-17 | 2019-01-11 | 大塚製藥股份有限公司 | 活化輔助ｔ細胞的方法 |
-
2013
- 2013-12-16 TW TW102146368A patent/TWI646970B/zh active
- 2013-12-16 CN CN201380065804.3A patent/CN104995203B/zh active Active
- 2013-12-16 CA CA2892660A patent/CA2892660C/en active Active
- 2013-12-16 AU AU2013365067A patent/AU2013365067B2/en active Active
- 2013-12-16 BR BR112015013697A patent/BR112015013697A2/pt not_active IP Right Cessation
- 2013-12-16 ES ES13864968T patent/ES2805337T3/es active Active
- 2013-12-16 EP EP13864968.6A patent/EP2933261B1/en active Active
- 2013-12-16 AR ARP130104756A patent/AR094026A1/es unknown
- 2013-12-16 MY MYPI2015701777A patent/MY175935A/en unknown
- 2013-12-16 CN CN201910520821.0A patent/CN110195040A/zh active Pending
- 2013-12-16 SG SG11201504530VA patent/SG11201504530VA/en unknown
- 2013-12-16 KR KR1020157018417A patent/KR102158225B1/ko active IP Right Grant
- 2013-12-16 JP JP2014553122A patent/JP6530192B2/ja active Active
- 2013-12-16 UA UAA201507132A patent/UA118962C2/uk unknown
- 2013-12-16 EA EA201591168A patent/EA201591168A1/ru unknown
- 2013-12-16 NZ NZ708990A patent/NZ708990A/en unknown
- 2013-12-16 SG SG10201705028WA patent/SG10201705028WA/en unknown
- 2013-12-16 WO PCT/JP2013/083580 patent/WO2014098012A1/ja active Application Filing
- 2013-12-16 US US14/652,298 patent/US9833493B2/en active Active
- 2013-12-16 MX MX2015007745A patent/MX2015007745A/es unknown
-
2015
- 2015-05-28 IL IL239056A patent/IL239056A0/en unknown
- 2015-06-16 PH PH12015501361A patent/PH12015501361A1/en unknown
-
2016
- 2016-04-20 HK HK16104510.5A patent/HK1216755A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015501361B1 (en) | 2015-09-02 |
| SG11201504530VA (en) | 2015-07-30 |
| PH12015501361A1 (en) | 2015-09-02 |
| US20150328278A1 (en) | 2015-11-19 |
| MX2015007745A (es) | 2015-12-15 |
| NZ708990A (en) | 2020-03-27 |
| EP2933261B1 (en) | 2020-06-10 |
| HK1216755A1 (zh) | 2016-12-02 |
| CA2892660C (en) | 2022-02-15 |
| KR20150096697A (ko) | 2015-08-25 |
| AU2013365067B2 (en) | 2017-10-05 |
| TWI646970B (zh) | 2019-01-11 |
| EP2933261A4 (en) | 2016-07-06 |
| EA201591168A1 (ru) | 2016-05-31 |
| TW201429487A (zh) | 2014-08-01 |
| MY175935A (en) | 2020-07-15 |
| JP6530192B2 (ja) | 2019-06-12 |
| CA2892660A1 (en) | 2014-06-26 |
| ES2805337T3 (es) | 2021-02-11 |
| IL239056A0 (en) | 2015-07-30 |
| AU2013365067A1 (en) | 2015-07-09 |
| EP2933261A1 (en) | 2015-10-21 |
| KR102158225B1 (ko) | 2020-09-21 |
| CN104995203A (zh) | 2015-10-21 |
| US9833493B2 (en) | 2017-12-05 |
| UA118962C2 (uk) | 2019-04-10 |
| BR112015013697A2 (pt) | 2017-11-14 |
| SG10201705028WA (en) | 2017-07-28 |
| JPWO2014098012A1 (ja) | 2017-01-12 |
| CN104995203B (zh) | 2019-06-28 |
| CN110195040A (zh) | 2019-09-03 |
| WO2014098012A1 (ja) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094026A1 (es) | Metodo para activar la celula t helper | |
| CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
| CY1126136T1 (el) | Μεθοδοι θεραπειας της αρθριτιδας | |
| BR112017016681A2 (pt) | vetor de coexpressão de vacina e moléculas coestimulatórias | |
| UY32874A (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
| CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| CR20150326A (es) | Inhibidores de autotaxina | |
| CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
| PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
| CU20170056A7 (es) | Métodos para tratar infecciones por el virus filoviridae | |
| BR112016013493A2 (pt) | molécula de ácido nucleico, composição, vacina, e, métodos para prevenção de uma doença em um indivíduo com necessidade da mesma e para tratamento de uma doença em um indivíduo com necessidade do mesmo | |
| CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| CU20170162A7 (es) | Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen | |
| AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
| CL2013000063A1 (es) | Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion. | |
| UY35147A (es) | Anticuerpos anti-ceacam5 y usos de éstos. | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| UY36075A (es) | Derivados de tubulisina | |
| AR101455A1 (es) | Molécula portadora | |
| CO6690760A2 (es) | Variantes no lipidadas de antígenos orf2086 de neisseria meningitidis | |
| DOP2015000076A (es) | Benzamidas | |
| CY1124512T1 (el) | Εμβολια καρκινου που στοχευουν καρκινικα βλαστοκυτταρα | |
| CR20140475A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| CR20130569A (es) | Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |